Perspectives for systems biology in the management of tuberculosis.
Perspectives for systems biology in the management of tuberculosis.
复制标题
DOI：
10.1183/16000617.0377-2020
复制
发表时间：
2021-06-30
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
结核病的标准化管理可能很快就会被个体化、精确的医学指导疗法所取代，这些疗法将由系统生物学领域提供的知识所告知。系统生物学是一个快速扩展的计算和数学分析领域，可以为结核病的潜在机制提供见解，识别新的生物标志物，并帮助优化疾病的预防，诊断和治疗。在耐药结核病不断演变的情况下，这些进展至关重要。在这里，我们回顾了系统生物学方法-人类和分枝杆菌基因组学和转录组学，蛋白质组学，脂质组学/代谢组学，免疫表型，系统药理学和肠道微生物组学-在结核病管理中的作用，包括预测疾病进展的风险，分枝杆菌毒力和耐药性的严重程度，不良事件，合并症，对治疗的反应和治疗结果。建议、评估、发展和评价分级（GRADE）方法的应用表明，目前大多数研究提供的回答临床相关问题的证据确定性“非常低”。需要在大型前瞻性患者队列中进行进一步研究，包括随机临床试验，以评估这些发现在结核病预防和更有效的患者临床管理中的适用性。我们正处在一个新时代的门槛上，系统生物学方法将有助于结核病患者的管理，包括预测疾病进展和严重程度的风险，对治疗的反应和治疗结果。https://bit.ly/36DQegb
Standardised management of tuberculosis may soon be replaced by individualised, precision medicine-guided therapies informed with knowledge provided by the field of systems biology. Systems biology is a rapidly expanding field of computational and mathematical analysis and modelling of complex biological systems that can provide insights into mechanisms underlying tuberculosis, identify novel biomarkers, and help to optimise prevention, diagnosis and treatment of disease. These advances are critically important in the context of the evolving epidemic of drug-resistant tuberculosis. Here, we review the available evidence on the role of systems biology approaches – human and mycobacterial genomics and transcriptomics, proteomics, lipidomics/metabolomics, immunophenotyping, systems pharmacology and gut microbiomes – in the management of tuberculosis including prediction of risk for disease progression, severity of mycobacterial virulence and drug resistance, adverse events, comorbidities, response to therapy and treatment outcomes. Application of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach demonstrated that at present most of the studies provide “very low” certainty of evidence for answering clinically relevant questions. Further studies in large prospective cohorts of patients, including randomised clinical trials, are necessary to assess the applicability of the findings in tuberculosis prevention and more efficient clinical management of patients. We are at the doorstep of a new era in which systems biology approaches will contribute to the management of patients with tuberculosis including prediction of risk for disease progression and severity, response to therapy and treatment outcome. https://bit.ly/36DQegb
登录
查看更多内容
DOI：
10.1056/nejmoa1800474
发表时间：
2018-10-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
CRyPTIC Consortium and the 100,000 Genomes Project;Allix-Béguec C;Arandjelovic I;Bi L;Beckert P;Bonnet M;Bradley P;Cabibbe AM;Cancino-Muñoz I;Caulfield MJ;Chaiprasert A;Cirillo DM;Clifton DA;Comas I;Crook DW;De Filippo MR;de Neeling H;Diel R;Drobniewski FA;Faksri K;Farhat MR;Fleming J;Fowler P;Fowler TA;Gao Q;Gardy J;Gascoyne-Binzi D;Gibertoni-Cruz AL;Gil-Brusola A;Golubchik T;Gonzalo X;Grandjean L;He G;Guthrie JL;Hoosdally S;Hunt M;Iqbal Z;Ismail N;Johnston J;Khanzada FM;Khor CC;Kohl TA;Kong C;Lipworth S;Liu Q;Maphalala G;Martinez E;Mathys V;Merker M;Miotto P;Mistry N;Moore DAJ;Murray M;Niemann S;Omar SV;Ong RT;Peto TEA;Posey JE;Prammananan T;Pym A;Rodrigues C;Rodrigues M;Rodwell T;Rossolini GM;Sánchez Padilla E;Schito M;Shen X;Shendure J;Sintchenko V;Sloutsky A;Smith EG;Snyder M;Soetaert K;Starks AM;Supply P;Suriyapol P;Tahseen S;Tang P;Teo YY;Thuong TNT;Thwaites G;Tortoli E;van Soolingen D;Walker AS;Walker TM;Wilcox M;Wilson DJ;Wyllie D;Yang Y;Zhang H;Zhao Y;Zhu B
通讯作者：
Zhu B
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
9.4
作者：
De Groote, Mary A.;Sterling, David G.;Ochsner, Urs A.
通讯作者：
Ochsner, Urs A.
基于数据独立采集和靶向蛋白质组学，血清 sCD14、PGLYRP2 和 FGA 作为耐多药结核病的潜在生物标志物
影响因子：
5.3
作者：
Chen J;Han YS;Yi WJ;Huang H;Li ZB;Shi LY;Wei LL;Yu Y;Jiang TT;Li JC
通讯作者：
Li JC
DOI：
10.1007/s00335-018-9765-4
发表时间：
2018-08
期刊：
Mammalian genome : official journal of the International Mammalian Genome Society
影响因子：
--
作者：
Dallmann-Sauer M;Correa-Macedo W;Schurr E
通讯作者：
Schurr E